SYNTHESIS OF A HEXADECASACCHARIDE FRAGMENT OF THE O-POLYSACCHARIDE OF SHIGELLA-DYSENTERIAE TYPE-1

被引:47
作者
POZSGAY, V
机构
[1] Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda
关键词
D O I
10.1021/ja00130a004
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A synthetic route is described to a hexadecasaccharide fragment of the O-polysaccharide portion of the lipopolysaccharide of Shigella dysenteriae type 1, a Gram-negative human pathogen. The key intermediate was a trichloroacetimidate derivative of the tetrasaccharide Rha alpha 1-->2Gal alpha 1-->3GlcNAc alpha 1-->3Rha alpha 1-->3 (23) which corresponds to a complete repeating unit of this polysaccharide. Important stages involved the stereoselective construction of a GlcNAc alpha 1-->3Rha synthon (7) which was transformed into a glycosyl acceptor (13) that was alpha-galactosylated in a stereocontrolled reaction with a thiogalactoside donor (14). Conversion of the Gal alpha 1-->3GlcNAc alpha 1-->3Rha intermediate 15 into the glycosyl acceptor 17 followed by stereoselective alpha-rhamnosylation afforded the fully protected tetrasaccharide glycoside from which the tetrasaccharide donor 23 was prepared that contains a selectively removable, benzyl protecting group at the site of the chain extension. The donor was first coupled with 1-decanol to give the tetrasaccharide glycoside 24. One-step conversion provided the tetrasaccharide acceptor 25. Subsequent, iterative glycosylations with the donor 23, used in excess, afforded the fully protected octa-, dodeca-, and hexadecasaccharides, conventional deprotection of which led to di- (2), tri- (3), and tetrameric (4) repeating units of the O-polysaccharide of Sh. dysenteriae type 1.
引用
收藏
页码:6673 / 6681
页数:9
相关论文
共 73 条
[1]  
Bacterial endotoxin: recognition and effector mechanisms, (1993)
[2]  
Robbins J.B., Schneerson R., J. Infect. Dis., 161, (1990)
[3]  
Robbins J.B., Chu C., Schneerson R., Clin. Inf. Dis., 15, (1992)
[4]  
Harding C.V., Kihlberg J., Elofsson M., Magnusson G., Unanue E.R., J. Immunol., 151, (1993)
[5]  
Ishioka G.Y., Lamont A.G., Thomson D., Bulbow N., Gaeta F.C.A., Sette A., Grey H.M., J. Immunol., 148, (1992)
[6]  
Dick W.E., Beurret M., Contrib. Microbiol. Immunol., 10, (1989)
[7]  
Egan W., Annu. Rep. Med. Chem., 28, (1993)
[8]  
Ishioka Lamont A.G., Thompson D., Bulbow F., Gaeta F.C.A., Sette A., Grey H.M., J. Immunol., 148, (1992)
[9]  
Harding C.V., Kihlberg J., Elofsson M., Magnusson G., Unanue E.R., J. Immunol., 151, (1993)
[10]  
Paradiso P.R., Dermody K., Pillai S., Vaccine Res., 2, (1993)